AstraZeneca Says Evusheld Effective in Trials With High-Risk Covid-19 Patients
08 Junho 2022 - 04:00AM
Dow Jones News
By Jaime Llinares Taboada
AstraZeneca PLC said Wednesday that trials on high-risk patients
showed that the Evusheld drug provides significant protection
against Covid-19.
The pharmaceutical company said that a single dose of Evusheld
reduced the risk of progressing to severe Covid-19 or death by 50%
in non-hospitalized patients with mild-to-moderate Covid-19. In
those who received treatment within three days of symptom onset,
the medicine reduced the risk by 88%.
The Tackle Phase 3 trial involved 903 adults across the U.S.,
Latin America, Europe and Japan.
"We are discussing the Tackle data with regulatory authorities
and continue to progress submissions in both treatment and
prophylaxis indications to help combat Covid-19 on all fronts,"
Executive Vice President Mene Pangalos said.
Write to Jaime Llinares Taboada at jaime.llinares@wsj.com;
@JaimeLlinaresT
(END) Dow Jones Newswires
June 08, 2022 02:45 ET (06:45 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024